Ticagrelor

Back to search

Molecule Structure

Scientific Name

Ticagrelor

Description of the Drug

Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08816

Brand Name(s)

Brilinta, Brilique

Company Owner(s)

Hisun Pharmaceutical Hangzhou Co Ltd, Sunshine Lake Pharma Co Ltd, Sigmapharm Laboratories Llc, Astrazeneca Pharmaceuticals Lp, Watson Laboratories Inc, Mylan Pharmaceuticals Inc, Amneal Eu Ltd

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Purinergic receptor P2Y12 SINGLE PROTEIN NEGATIVE ALLOSTERIC MODULATOR CHEMBL2001

Unichem Links

SureChEMBL SCHEMBL1979652
PharmGKB PA165374673
Human Metabolome Database HMDB0015702
DrugBank DB08816
PubChem: Thomson Pharma 14860737 14836432
PubChem 9871419
Nikkaji J1.905.358J
PDBe TIQ
BindingDB 50397205
DrugCentral 4184
ChemicalBook CB51509134
Guide to Pharmacology 1765
rxnorm BRILINTA TICAGRELOR
PubChem: Drugs of the Future 49684205
ChEBI 68558
ZINC ZINC000028957444